Search Results
Found 1 results
510(k) Data Aggregation
(368 days)
OCS-B COLLAGEN
OCS-B Collagen® is recommended for:
- Augmentation or reconstructive treatment of the alveolar ridge.
- Filling of infrabony periodontal defects.
- Filling of defects after root resection, apicoectomy, and cystectomy
- Filling of extraction sockets to enhance preservation of the alveolar ridge
- Elevation of maxillary sinus floor
- Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR)
- Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR)
OCS-B Collagen® is a combination of purified cancellous bone mineral granules (OCS-B") and 10% collagen in a block form in a blister and cylinderic form in a syringe and blister. It is sterilized by yirradiation.
The provided text describes the OCS-B Collagen® device, a bone grafting material, and its substantial equivalence to predicate devices, primarily Bio-Oss Collagen®. The information requested falls under the category of performance testing for medical devices, which typically includes detailed studies to prove efficacy and safety. However, this document is a 510(k) summary, which focuses on demonstrating "substantial equivalence" to existing legally marketed devices rather than performing extensive novel clinical trials as would be required for a novel device or a PMA.
Therefore, the study described here is primarily a comparative study against predicate devices, supported by biocompatibility testing and animal studies, rather than a standalone clinical efficacy study with specific acceptance criteria in terms of performance metrics like sensitivity, specificity, or improvement with AI assistance.
Here's the breakdown based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are not explicitly stated in terms of quantitative performance metrics (e.g., specific percentages for success rates, bone growth, etc.). Instead, the acceptance criteria are implicitly that the OCS-B Collagen® device is "substantially equivalent" to its predicate devices (Bio-Oss® Collagen and OCS-B®) in terms of:
Acceptance Criterion (Implicit) | Reported Device Performance |
---|---|
Same Indications for Use | OCS-B Collagen® has the same indications for use as Bio-Oss® Collagen, including augmentation/reconstructive treatment of alveolar ridge, filling of infrabony periodontal defects, defects after root resection/apicoectomy/cystectomy, extraction sockets, elevation of maxillary sinus floor, and filling of periodontal/peri-implant defects in conjunction with GTR/GBR. |
Same Intended Use | OCS-B Collagen® has the same intended use as Bio-Oss® Collagen and OCS-B® (adjective therapy in restoring bony defects). |
Similar Physical and Chemical Structure | Both OCS-B Collagen® and Bio-Oss® Collagen are porous, biocompatible bone grafts facilitating new bone formation. They have the same component ratio of bone mineral granules and collagen, same source of bone (bovine bone), and collagen (porcine skin). Physical and chemical characteristics were found to be comparable. |
Comparable Biocompatibility | OCS-B Collagen® was subjected to a full range of biocompatibility tests (ISO 10993, cytotoxicity, hemolysis, acute systemic injection, intracutaneous reactivity, skin sensitization, genotoxicity, oral mucosa irritation, implantation) and confirmed equivalence to predicates. |
Similar Performance in Animal Studies (Bone Growth and Resorption) | In several animal studies, both OCS-B Collagen® and predicate devices were found to grow new bone and be subsequently resorbed at similar rates. |
Successful Clinical Outcomes (Case Series) | A clinical case series using OCS-B Collagen® resulted in defect healing and formation of new bone of sufficient quality to allow dental implant placement. |
Same Sterilization Process | Sterile by Gamma Irradiation (SAL 1 x 10⁻⁶). |
Same Shelf-Life | 36 Months. |
Compliance with Relevant Standards (ASTM F1581-99, FDA "Medical Device Materials Derived from Animal Sources", ISO 11137, ASTM F1980-99) | OCS-B Collagen® was tested in accordance with these standards. (Compliance implies meeting the requirements set forth in these standards, but specific results against numerical criteria are not detailed in this summary). |
Controlled Risks | OCS-B Collagen® presents the same types of potential risks as the predicate and controls these risks in a similar manner (e.g., manufacturing processes for removal of organic impurities, protein content limits, TSE/virus inactivation studies). |
2. Sample Size Used for the Test Set and Data Provenance
- Animal Studies: "several animal studies" are mentioned, but no specific sample sizes or species are provided in this summary document.
- Clinical Case Series: "a clinical case series" is mentioned, but no specific number of patients (sample size) is provided.
- Data Provenance: Not explicitly stated for animal studies or the clinical case series (e.g., country of origin, retrospective/prospective). However, the sponsor is NIBEC Co., Ltd. from Korea. Given the K-number, the submission is to the U.S. FDA, so the data would have been submitted to the U.S. regulatory body. The document does not specify if these studies are retrospective or prospective.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts
This type of information is generally not applicable to the studies described for this device. The "ground truth" here is the biological and clinical outcome (bone formation, resorption, defect healing, suitability for implant placement), which would be assessed by standard histological, imaging, and clinical follow-up methods by trained professionals (e.g., veterinarians for animal studies, dentists/oral surgeons for clinical case series). The document does not specify an "expert panel" for establishing ground truth in the context of, for example, image interpretation.
4. Adjudication Method for the Test Set
Not applicable in the context of this 510(k) summary. Adjudication methods (like 2+1, 3+1) are typically used for studies where multiple human readers interpret data (e.g., images) and consensus is needed, often in AI comparative effectiveness studies. The studies mentioned here focus on biological outcomes rather than interpretive tasks.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done
No, an MRMC comparative effectiveness study was not conducted as described in this summary. The comparison is between the device and predicate devices based on physical/chemical properties, biocompatibility, and general performance in animal studies and a clinical case series, not a comparative study of human reader performance with and without AI assistance.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
This refers to an AI algorithm's performance, which is not relevant for this bone graft material. The device itself is a physical implant, not a diagnostic algorithm.
7. The Type of Ground Truth Used
The ground truth used in the animal studies and clinical case series would be based on:
- Histology: Direct examination of tissue to confirm new bone formation and resorption.
- Imaging: X-rays, CT scans, or other imaging modalities to assess defect healing and bone density/volume.
- Clinical Outcomes: Assessment of defect healing, absence of adverse events, and functional outcomes, such as successful dental implant placement.
8. The Sample Size for the Training Set
Not applicable. This device is a physical bone graft, not a machine learning algorithm requiring a training set.
9. How the Ground Truth for the Training Set was Established
Not applicable, as there is no training set for a machine learning algorithm.
Ask a specific question about this device
Page 1 of 1